Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 03 2023
28 03 2023
Historique:
accepted:
06
04
2022
received:
29
11
2021
pubmed:
22
4
2022
medline:
22
3
2023
entrez:
21
4
2022
Statut:
ppublish
Résumé
We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(-) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(-) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.
Identifiants
pubmed: 35446936
pii: 485028
doi: 10.1182/bloodadvances.2021006716
pmc: PMC10027512
doi:
Substances chimiques
Immunosuppressive Agents
0
eltrombopag
S56D65XJ9G
Banques de données
ClinicalTrials.gov
['NCT03413306']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-962Informations de copyright
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
N Engl J Med. 2022 Jan 6;386(1):11-23
pubmed: 34986284
Exp Hematol. 2006 Jul;34(7):826-31
pubmed: 16797409
Blood. 2014 Mar 20;123(12):1818-25
pubmed: 24345753
Haematologica. 2014 Apr;99(4):664-71
pubmed: 24213150
Haematologica. 2009 May;94(5):712-9
pubmed: 19336743
Blood. 2011 Apr 28;117(17):4434-41
pubmed: 21233311
Blood. 2012 Jun 7;119(23):5391-6
pubmed: 22544699
Br J Haematol. 2015 May;169(4):565-73
pubmed: 25683884
Am J Hematol. 2014 Jun;89(6):571-4
pubmed: 24971433
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Cancer. 2018 Nov 1;124(21):4192-4201
pubmed: 30307606
J Pediatr. 2008 Dec;153(6):814-9
pubmed: 18672253
N Engl J Med. 2011 Aug 4;365(5):430-8
pubmed: 21812672
Clin Pharmacol Ther. 2018 Dec;104(6):1199-1207
pubmed: 29536526
Hematology Am Soc Hematol Educ Program. 2013;2013:76-81
pubmed: 24319166
Blood. 2017 Mar 16;129(11):1428-1436
pubmed: 28096088
Haematologica. 2014 Dec;99(12):1784-91
pubmed: 25193958
Pediatr Clin North Am. 2013 Dec;60(6):1311-36
pubmed: 24237973
Osteoporos Int. 2021 Jun;32(6):1227-1231
pubmed: 33244623
Br J Haematol. 2014 Feb;164(4):546-54
pubmed: 24261566
Haematologica. 2015 Dec;100(12):1546-52
pubmed: 26315930
Br J Haematol. 2021 Feb;192(3):605-614
pubmed: 33410523
Cytometry B Clin Cytom. 2018 Jan;94(1):49-66
pubmed: 29236350
Stem Cells. 2009 Feb;27(2):424-30
pubmed: 19038790
N Engl J Med. 2017 Apr 20;376(16):1540-1550
pubmed: 28423296
Lancet. 1988 Feb 6;1(8580):303-4
pubmed: 2893118
Int J Lab Hematol. 2020 Oct;42(5):589-593
pubmed: 32449605
Br J Haematol. 2015 Nov;171(4):585-94
pubmed: 26223288
Br J Haematol. 2008 Jan;140(2):197-205
pubmed: 18173756
Intern Med. 2021 Apr 15;60(8):1159-1168
pubmed: 33229810